PDA
MCID: PTN002
MIFTS: 52

Patent Ductus Arteriosus (PDA) malady

Categories: Rare diseases, Cardiovascular diseases, Genetic diseases

Aliases & Classifications for Patent Ductus Arteriosus

Aliases & Descriptions for Patent Ductus Arteriosus:

Name: Patent Ductus Arteriosus 12 50 13 14
Ductus Arteriosus, Patent 12 42
Patent Ductus Arteriosus - Persisting Type 69
Patent Ductus Arteriosus Familial 50
Patency of the Ductus Arteriosus 50
Ductus Arteriosus Patent 52
Patent Ductus Botalli 12
Pda1 50
Pda 50

Classifications:



External Ids:

Disease Ontology 12 DOID:13832
ICD10 33 Q25.0
ICD9CM 35 747.0
MeSH 42 D004374
NCIt 47 C84492
SNOMED-CT 64 156928009 83330001
UMLS 69 C0013274

Summaries for Patent Ductus Arteriosus

MalaCards based summary : Patent Ductus Arteriosus, also known as ductus arteriosus, patent, is related to patent ductus arteriosus 3 and char syndrome. An important gene associated with Patent Ductus Arteriosus is PRDM6 (PR/SET Domain 6), and among its related pathways/superpathways are Human Embryonic Stem Cell Pluripotency and Colorectal Cancer Metastasis. The drugs Acetaminophen and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 71 Patent ductus arteriosus (PDA) is a condition wherein the ductus arteriosus fails to close after... more...

Related Diseases for Patent Ductus Arteriosus

Diseases in the Patent Ductus Arteriosus family:

Patent Ductus Arteriosus 3

Diseases related to Patent Ductus Arteriosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
id Related Disease Score Top Affiliating Genes
1 patent ductus arteriosus 3 12.5
2 char syndrome 12.2
3 patent ductus arteriosus and bicuspid aortic valve with hand anomalies 12.2
4 intestinal pseudoobstruction with patent ductus arteriosus and natal teeth 12.2
5 pulmonary artery coming from patent ductus arteriosus 12.2
6 congenital patent ductus arteriosus aneurysm 12.2
7 multisystemic smooth muscle dysfunction syndrome 11.4
8 heterotaxy, visceral, 1, x-linked 11.3
9 hypertrichotic osteochondrodysplasia 11.3
10 gorlin-chaudhry-moss syndrome 11.3
11 patent arterial duct 11.3
12 aortic aneurysm, familial thoracic 4 11.3
13 cranioosteoarthropathy 11.2
14 axenfeld-rieger syndrome, type 3 11.2
15 femoral-facial syndrome 11.2
16 nephronophthisis 16 11.2
17 congenital heart defects, multiple types, 4 11.2
18 heterotopia, periventricular 11.2
19 nephronophthisis 20 11.2
20 pancreatic agenesis and congenital heart defects 11.2
21 premature closure of the arterial duct 11.2
22 natal teeth, intestinal pseudoobstruction and patent ductus 11.2
23 pulmonary valve agenesis-ventricular septal defect-persistent ductus arteriosus syndrome 11.0
24 ventricular septal defect 10.6
25 aneurysm 10.5
26 right aortic arch 10.5
27 pulmonary hypertension 10.5
28 aortic coarctation 10.4
29 endocarditis 10.4
30 cerebritis 10.3
31 autosomal recessive spastic paraplegia type 59 10.3 PRDM6 TFAP2B
32 eisenmenger syndrome 10.3
33 bronchopulmonary dysplasia 10.3
34 thrombocytopenia 10.2
35 heart disease 10.2
36 pulmonic stenosis 10.2
37 subacute bacterial endocarditis 10.2
38 rectal duplication 10.2 MYH11 PRDM6 TFAP2B
39 aortic aneurysm 10.2
40 coarctation of aorta 10.2
41 thoracic aortic aneurysm 10.2
42 neuropathy, hereditary sensory and autonomic, type vi 10.2 TBX5 TFAP2B TGFBR2
43 enamel hypoplasia cataract hydrocephaly 10.2 EDN1 TGFB1 TGFBR2
44 cardiomyopathy 10.1
45 tetralogy of fallot 10.1
46 esophagitis 10.1
47 coronary arterial fistulas 10.1
48 lung disease 10.1
49 intestinal perforation 10.1
50 pulmonary atresia with intact ventricular septum 10.0

Graphical network of the top 20 diseases related to Patent Ductus Arteriosus:



Diseases related to Patent Ductus Arteriosus

Symptoms & Phenotypes for Patent Ductus Arteriosus

MGI Mouse Phenotypes related to Patent Ductus Arteriosus:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 MATR3 MYH11 PRDM6 PTGER4 PTGS1 PTGS2
2 homeostasis/metabolism MP:0005376 10.25 CHD7 EDN1 GABBR2 GATA6 HPGD KCNJ8
3 cellular MP:0005384 10.23 PTGS1 PTGS2 TFAP2B TGFB1 TGFBR2 ABCC9
4 growth/size/body region MP:0005378 10.15 ABCC9 CHD7 EDN1 GABBR2 GATA6 MYH11
5 mortality/aging MP:0010768 10.11 ABCC9 CHD7 EDN1 GABBR2 GATA6 HPGD
6 embryo MP:0005380 10.01 CHD7 EDN1 GATA6 PRDM6 PTGS2 TBX5
7 digestive/alimentary MP:0005381 9.98 CHD7 EDN1 MYH11 PTGS1 PTGS2 TGFB1
8 integument MP:0010771 9.86 TGFB1 PTGER4 PTGS1 PTGS2 TFAP2B GABBR2
9 muscle MP:0005369 9.7 ABCC9 CHD7 EDN1 GATA6 MYH11 PTGS1
10 respiratory system MP:0005388 9.36 CHD7 GATA6 MYH11 PRDM6 PTGER4 PTGS1

Drugs & Therapeutics for Patent Ductus Arteriosus

Drugs for Patent Ductus Arteriosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1 103-90-2 1983
2
Ibuprofen Approved Phase 4,Phase 2,Phase 3,Phase 1 15687-27-1 3672
3
Indomethacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53-86-1 3715
4 Poractant alfa Approved Phase 4,Phase 3 129069-19-8
5 Beractant Approved Phase 4 108778-82-1
6 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
7 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
8 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
10 Antipyretics Phase 4,Phase 2,Phase 3,Phase 1
11 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
13 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
14 Pulmonary Surfactants Phase 4,Phase 3,Phase 2
15 Tocolytic Agents Phase 4,Phase 3,Phase 2
16 Respiratory System Agents Phase 4,Phase 3,Phase 2
17 Anti-Infective Agents Phase 4
18 Anti-Infective Agents, Local Phase 4
19 cadexomer iodine Phase 4
20
Iodine Phase 4 7553-56-2 807
21 Micronutrients Phase 4
22 Trace Elements Phase 4
23
Benzocaine Approved Phase 2, Phase 3 1994-09-7, 94-09-7 2337
24
Dexmedetomidine Approved, Vet_approved Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
25
Dopamine Approved Phase 2, Phase 3 51-61-6, 62-31-7 681
26
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
27
Fenoldopam Approved Phase 2, Phase 3 67227-56-9, 67227-57-0 3341
28 tannic acid Approved, Nutraceutical Phase 2, Phase 3
29
Caffeine Approved, Nutraceutical Phase 3 58-08-2 2519
30 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
31 Antioxidants Phase 3,Phase 2
32 Protective Agents Phase 3,Phase 2
33 Phosphodiesterase Inhibitors Phase 3,Phase 2
34 Vasodilator Agents Phase 2, Phase 3
35 Adrenergic Agents Phase 3
36 Adrenergic Agonists Phase 3
37 Adrenergic alpha-2 Receptor Agonists Phase 3
38 Adrenergic alpha-Agonists Phase 3
39 Central Nervous System Depressants Phase 3
40 Hypnotics and Sedatives Phase 3
41 Neurotransmitter Agents Phase 3,Phase 2
42
Bilirubin Phase 3 635-65-4 5280352
43 Anti-Asthmatic Agents Phase 3,Phase 2
44 Hormones Phase 3,Phase 2
45 Dopamine Agents Phase 2, Phase 3
46 Betamethasone benzoate Phase 3
47 Betamethasone sodium phosphate Phase 3
48 Betamethasone Valerate Phase 3 2152-44-5
49 Betamethasone-17,21-dipropionate Phase 3
50 glucocorticoids Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 134)
id Name Status NCT ID Phase
1 Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants Unknown status NCT01544972 Phase 4
2 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
3 Cpap at Delivery Room for Preterm Infants Unknown status NCT01024361 Phase 4
4 Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants Completed NCT01428180 Phase 4
5 Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial Completed NCT01536158 Phase 4
6 Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants Completed NCT00642330 Phase 4
7 Ibuprofen and Renal Function in Premature Infants Completed NCT00217191 Phase 4
8 A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years Completed NCT00638092 Phase 4
9 OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP Recruiting NCT02140580 Phase 4
10 Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates Terminated NCT00961753 Phase 4
11 Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Terminated NCT00767039 Phase 4
12 Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies Withdrawn NCT00470743 Phase 4
13 High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant Completed NCT01243996 Phase 2, Phase 3
14 Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus Completed NCT01593163 Phase 3
15 Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA Completed NCT00440804 Phase 3
16 Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA Completed NCT00485160 Phase 3
17 Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP) Completed NCT00009646 Phase 3
18 Management of Patent Ductus in Premature Infants Completed NCT00000494 Phase 3
19 The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease Completed NCT00480740 Phase 3
20 NIV Strategies for RDS in Preterm Infants. NIV (Non Invasive Ventilation), RDS (Respiratory Distress Syndrome) Completed NCT02259400 Phase 2, Phase 3
21 Canadian Oxygen Trial (COT) Completed NCT00637169 Phase 3
22 Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight Completed NCT00114543 Phase 3
23 Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants Recruiting NCT02002741 Phase 2, Phase 3
24 Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates Recruiting NCT03022253 Phase 3
25 Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI) Recruiting NCT01630278 Phase 3
26 Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants Recruiting NCT01755728 Phase 3
27 Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth Recruiting NCT02897076 Phase 3
28 Comparison of Two Flow Rates of HHHFNC to Prevent Extubation Failure in Preterm Infants Recruiting NCT02681315 Phase 3
29 L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia Active, not recruiting NCT01306227 Phase 3
30 Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants. Not yet recruiting NCT02056223 Phase 2, Phase 3
31 Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Not yet recruiting NCT02620761 Phase 2, Phase 3
32 An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants Terminated NCT00750581 Phase 2, Phase 3
33 Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation Terminated NCT01306240 Phase 3
34 Treating the Resistant Patent Ductus Arteriosus (PDA) Unknown status NCT00616382 Phase 2
35 Paracetamol and Patent Ductus Arteriosus (PDA) Unknown status NCT01291654 Phase 2
36 Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants Unknown status NCT01149564 Phase 1, Phase 2
37 Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants Unknown status NCT00910234 Phase 1, Phase 2
38 Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM) Unknown status NCT00466128 Phase 2
39 Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus Completed NCT00187447 Phase 2
40 Safety and Effectiveness of the Device "Nit-Occlud® PDA-R" Completed NCT01063712 Phase 2
41 The Preterm Infants' Paracetamol Study Completed NCT01938261 Phase 2
42 Ventilatory Management of the Preterm Neonate in the Delivery Room Completed NCT01255826 Phase 2
43 The Best Treatment Strategy: Surgical vs Pharmacological to Close the Ductus Arteriosus Persistent in Preterm Infants Recruiting NCT02602054 Phase 2
44 Paracetamol in Patent Ductus Arteriosus Recruiting NCT02422966 Phase 2
45 Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus Recruiting NCT01958320 Phase 2
46 Chest Shielding in Premature Infants During Phototherapy Recruiting NCT02552927 Phase 2
47 No Treatment Versus Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants Recruiting NCT02128191 Phase 2
48 Paracetamol Treatment of the Borderline Significant PDA Active, not recruiting NCT02819414 Phase 2
49 Impact of the Administration of Fludrocortisone in Very Premature Infants Not yet recruiting NCT03001089 Phase 2
50 Inhaled Budesonide for Non-ventilated Infants at High Risk of Bronchopulmonary Dysplasia: the i-BUD Pilot Study Not yet recruiting NCT01895075 Phase 2

Search NIH Clinical Center for Patent Ductus Arteriosus

Cochrane evidence based reviews: ductus arteriosus, patent

Genetic Tests for Patent Ductus Arteriosus

Anatomical Context for Patent Ductus Arteriosus

MalaCards organs/tissues related to Patent Ductus Arteriosus:

39
Lung, Heart, Brain, Testes, Smooth Muscle, Neutrophil, Eye

Publications for Patent Ductus Arteriosus

Articles related to Patent Ductus Arteriosus:

(show top 50) (show all 720)
id Title Authors Year
1
Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. ( 28004188 )
2017
2
Urinary Neutrophil Gelatinase-associated Lipocalin in the evaluation of Patent Ductus Arteriosus and AKI in Very Preterm Neonates: a cohort study. ( 28068947 )
2017
3
Efficacy and Safety of Rectal Ibuprofen for Patent Ductus Arteriosus Closure in Very Low Birth Weight Preterm Infants. ( 28052714 )
2017
4
Percutaneous Patent Ductus Arteriosus (PDA) Closure During Infancy: A Meta-analysis. ( 28087683 )
2017
5
Simultaneous transcatheter therapy for perimembranous ventricular septal defect combined with patent ductus arteriosus. ( 28497553 )
2017
6
Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants. ( 28046188 )
2017
7
Minimally invasive thoracoscopic closure versus thoracotomy in children with patent ductus arteriosus. ( 27993195 )
2017
8
Lung function in very low birth weight infants after pharmacological and surgical treatment of patent ductus arteriosus - a retrospective analysis. ( 28056907 )
2017
9
Comparison of the Mortality and In-Hospital Outcomes of Preterm Infants Treated with Ibuprofen for Patent Ductus Arteriosus with or without Clinical Symptoms Attributable to the Patent Ductus Arteriosus at the Time of Ibuprofen Treatment. ( 27914140 )
2017
10
Echocardiographic assessment of patent ductus arteriosus in very low birthweight infants over time: prospective observational study. ( 28043190 )
2017
11
Comparison of effectiveness and cost of patent ductus arteriosus device occlusion versus surgical ligation of patent ductus arteriosus. ( 27648051 )
2016
12
Reflections of the changes in patent ductus arteriosus management during the last 10a88years. ( 27118761 )
2016
13
Elevated Nucleated Red Blood Cells at Birth Predict Hemodynamically Significant Patent Ductus Arteriosus. ( 27522442 )
2016
14
Patent ductus arteriosus in cats (Felis catus): 50 cases (2000-2015). ( 27919727 )
2016
15
Patent Ductus Arteriosus in the Preterm Infant: An Update on Morbidity and Mortality. ( 27197950 )
2016
16
Nursing Assessment, Education, and Care of Extremely Premature Neonates with Patent Ductus Arteriosus. ( 27197951 )
2016
17
Principles of Clinical Management of Patent Ductus Arteriosus in Extremely Preterm Neonates. ( 27197949 )
2016
18
Echocardiographic Assessment of Cardiac Function by Conventional and Speckle-Tracking Echocardiography in Dogs with Patent Ductus Arteriosus. ( 27177624 )
2016
19
Mutations in the Histone Modifier PRDM6 Are Associated with Isolated Nonsyndromic Patent Ductus Arteriosus. ( 27181681 )
2016
20
A Survey among Neonatologists on the Management of Patent Ductus Arteriosus. ( 28000109 )
2016
21
Pathophysiology of Patent Ductus Arteriosus in the Preterm Infant. ( 27197953 )
2016
22
Trends and Outcomes of Patent Ductus Arteriosus Treatment in Very Preterm Infants in Canada. ( 27649293 )
2016
23
Single nucleotide polymorphisms in AGTR1, TFAP2B, and TRAF1 are not associated with the incidence of patent ductus arteriosus in Japanese preterm infants. ( 26615960 )
2016
24
Surgical Ligation for Patent Ductus Arteriosus in Extremely Premature Infants: Strategy to Reduce their Risk of Neurodevelopmental Impairment. ( 27558322 )
2016
25
Isolation of Left Common Carotid Artery with Its Origin Proximal to Patent Ductus Arteriosus Presenting in Adult Age. ( 27213071 )
2016
26
Follow-Up Results of Device Occlusion of Patent Ductus Arteriosus. ( 27617065 )
2016
27
Alternative methods for the measurement of the minimal ductal diameter of a patent ductus arteriosus in a dog. ( 27665538 )
2016
28
Patent ductus arteriosus illuminating an old eponym. ( 27154278 )
2016
29
The Value of Carina Angle Measurement for the Diagnosis of Patent Ductus Arteriosus. ( 27617754 )
2016
30
Bilateral Congenital Iris Sphincter Agenesis Diagnosed After Massive Bleeding Episode During Repair of Aneurysmal Dilation of Patent Ductus Arteriosus. ( 27898547 )
2016
31
Effect of patent ductus arteriosus and patent foramen ovale on left ventricular stroke volume measurement by electrical velocimetry in comparison to transthoracic echocardiography in neonates. ( 27072988 )
2016
32
Counter-clockwise vortical blood flow in the main pulmonary artery in a patient with patent ductus arteriosus with pulmonary arterial hypertension: a cardiac magnetic resonance imaging case report. ( 27501792 )
2016
33
Speckle-Tracking Echocardiography in Dogs With Patent Ductus Arteriosus: Effect of Percutaneous Closure on Cardiac Mechanics. ( 27177625 )
2016
34
Mutations in the Histone Modifier PRDM6 Are Associated with Isolated Nonsyndromic Patent Ductus Arteriosus. ( 27716515 )
2016
35
Surgical Intervention in Preterm Neonates with Patent Ductus Arteriosus. ( 27197954 )
2016
36
A Case of Patent Ductus Arteriosus in an Elderly Patient Treated by Thoracic Endovascular Aortic Repair. ( 28018507 )
2016
37
Correlation of B-type natriuretic peptide levels and echocardiographic parameters in preterm infants with patent ductus arteriosus. ( 27186229 )
2016
38
Trends and Variation in Management and Outcomes of Very Low Birth Weight Infants with Patent Ductus Arteriosus. ( 27509008 )
2016
39
Management of Patent Ductus Arteriosus: Are We Looking at the Right Outcomes? ( 28041670 )
2016
40
An Elevation of Serum Ferritin Level Might Increase Clinical Risk for the Persistence of Patent Ductus Arteriosus, Sepsis and Bronchopulmonary Dysplasia in Erythropoietin-Treated Very-Low-Birth-Weight Infants. ( 27547966 )
2016
41
Patent Ductus Arteriosus Banding for Circular Shunting After Pulmonary Valvuloplasty. ( 27647342 )
2016
42
Short-Term Outcomes of Patent Ductus Arteriosus Closure With New OcclutechAr Duct Occluder: A Multicenter Study. ( 27090770 )
2016
43
A Hemodynamically Significant Patent Ductus Arteriosus Does Not Affect Cerebral or Renal Tissue Oxygenation in Preterm Infants. ( 27088709 )
2016
44
Shunt Lesions Part I: Patent Ductus Arteriosus, Atrial Septal Defect, Ventricular Septal Defect, and Atrioventricular Septal Defect. ( 27490614 )
2016
45
The Role of Paracetamol for Closing Patent Ductus Arteriosus. A Challenging Alternative for Ductal Closure? ( 27499419 )
2016
46
Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants. ( 27998626 )
2016
47
Transcatheter Echocardiographic-Guided Closure of Patent Ductus Arteriosus in Extremely Premature Newborns. ( 27931596 )
2016
48
The use of whole thoracic ECG-gated MDCT for the de novo diagnosis of isolated patent ductus arteriosus in middle aged or older subjects. ( 27611919 )
2016
49
Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. ( 27908647 )
2016
50
Pharmacotherapy for Patent Ductus Arteriosus: Current Options and Outstanding Questions. ( 27197952 )
2016

Variations for Patent Ductus Arteriosus

Expression for Patent Ductus Arteriosus

Search GEO for disease gene expression data for Patent Ductus Arteriosus.

Pathways for Patent Ductus Arteriosus

GO Terms for Patent Ductus Arteriosus

Cellular components related to Patent Ductus Arteriosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP-sensitive potassium channel complex GO:0008282 8.62 ABCC9 KCNJ8

Biological processes related to Patent Ductus Arteriosus according to GeneCards Suite gene sharing:

(show all 36)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.93 PTGS2 TBX5 TFAP2B TGFB1 TGFBR2
2 regulation of cell proliferation GO:0042127 9.89 PTGS1 PTGS2 TGFB1 TGFBR2
3 in utero embryonic development GO:0001701 9.85 CHD7 EDN1 GATA6 TGFBR2
4 cellular response to hypoxia GO:0071456 9.84 EDN1 GATA6 PTGS2
5 kidney development GO:0001822 9.84 HPGD KCNJ8 TFAP2B
6 response to estradiol GO:0032355 9.83 HPGD PTGS2 TGFB1
7 response to organic substance GO:0010033 9.83 PTGS2 TGFB1 TGFBR2
8 transforming growth factor beta receptor signaling pathway GO:0007179 9.82 HPGD TGFB1 TGFBR2
9 heart development GO:0007507 9.8 EDN1 KCNJ8 TBX5 TGFB1 TGFBR2
10 cellular response to mechanical stimulus GO:0071260 9.77 PTGER4 PTGS2 TGFB1
11 response to lipopolysaccharide GO:0032496 9.72 EDN1 HPGD KCNJ8 PTGER4 PTGS2
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.7 EDN1 PTGS2 TGFBR2
13 regulation of blood vessel size GO:0050880 9.67 EDN1 NPPB
14 lipoxygenase pathway GO:0019372 9.66 HPGD PTGS2
15 aorta morphogenesis GO:0035909 9.65 CHD7 TFAP2B
16 positive regulation of renal sodium excretion GO:0035815 9.64 EDN1 NPPB
17 ovulation GO:0030728 9.63 HPGD PTGS2
18 pathway-restricted SMAD protein phosphorylation GO:0060389 9.63 TGFB1 TGFBR2
19 cyclooxygenase pathway GO:0019371 9.62 PTGS1 PTGS2
20 forelimb morphogenesis GO:0035136 9.61 TBX5 TFAP2B
21 atrioventricular valve morphogenesis GO:0003181 9.61 TBX5 TGFBR2
22 negative regulation of cell cycle GO:0045786 9.61 HPGD PTGS2 TGFB1
23 response to lithium ion GO:0010226 9.58 PTGS2 TFAP2B
24 negative regulation of cardiac muscle cell proliferation GO:0060044 9.58 TBX5 TGFBR2
25 body fluid secretion GO:0007589 9.57 EDN1 NPPB
26 response to cholesterol GO:0070723 9.56 TGFB1 TGFBR2
27 regulation of blood pressure GO:0008217 9.56 EDN1 NPPB PTGS1 PTGS2
28 prostaglandin metabolic process GO:0006693 9.54 HPGD PTGS1 PTGS2
29 common-partner SMAD protein phosphorylation GO:0007182 9.51 TGFB1 TGFBR2
30 ductus arteriosus closure GO:0097070 9.49 HPGD TFAP2B
31 positive regulation of cardioblast differentiation GO:0051891 9.48 GATA6 TBX5
32 positive regulation of odontogenesis GO:0042482 9.46 EDN1 TGFB1
33 prostaglandin biosynthetic process GO:0001516 9.33 EDN1 PTGS1 PTGS2
34 response to drug GO:0042493 9.17 ABCC9 EDN1 GATA6 PTGS2 TFAP2B TGFB1
35 positive regulation of urine volume GO:0035810 9.13 EDN1 NPPB TFAP2B
36 positive regulation of cell proliferation GO:0008284 10.02 EDN1 PTGS2 TFAP2B TGFB1 TGFBR2

Molecular functions related to Patent Ductus Arteriosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 type I transforming growth factor beta receptor binding GO:0034713 9.16 TGFB1 TGFBR2
2 prostaglandin E receptor activity GO:0004957 8.96 HPGD PTGER4
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Patent Ductus Arteriosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....